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Inhibitors of checkpoint kinases ATR, Chk1, and Wee1 are currently being tested in
preclinical and clinical trials. Here, we review the basic principles behind the use of such
inhibitors as anticancer agents, and particularly discuss their potential for treatment of
lung cancer. As lung cancer is one of the most deadly cancers, new treatment strategies
are highly needed. We discuss how checkpoint kinase inhibition in principle can lead
to selective killing of lung cancer cells while sparing the surrounding normal tissues.
Several features of lung cancer may potentially be exploited for targeting through inhibition
of checkpoint kinases, including mutated p53, low ERCC1 levels, amplified Myc, tumor
hypoxia and presence of lung cancer stem cells. Synergistic effects have also been
reported between inhibitors of ATR/Chk1/Wee1 and conventional lung cancer treatments,
such as gemcitabine, cisplatin, or radiation. Altogether, inhibitors of ATR, Chk1, and Wee1
are emerging as new cancer treatment agents, likely to be useful in lung cancer treatment.
However, as lung tumors are very diverse, the inhibitors are unlikely to be effective in all
patients, and more work is needed to determine how such inhibitors can be utilized in the
most optimal ways.
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INTRODUCTION
Lung cancer is difficult to treat. Its frequent incidence combined
with the low success rate of current treatment strategies, make
lung cancer the overall deadliest form of cancer worldwide (Siegel
et al., 2012). Although recent progress has demonstrated drug-
gable driver mutations in lung cancer, such as ALK (Anaplastic
Lymphoma Kinase) translocations and EGFR (Epidermal Growth
Factor Receptor) mutations, these are found only in a small subset
of all lung cancer patients, and treatment resistance develops
invariable (Chen et al., 2014). Most patients are diagnosed in late
stages of the disease and are treated with chemotherapy or radio-
therapy, with symptomatic and sometimes life prolonging effect.
Overall, 5 years survival is bleak, approaching 18% (National
Institutes of Health, 2011; Cancer Registry of Norway, 2012).
There is therefore still a strong need for development of new
treatment strategies in lung cancer.
In response to DNA damage or replication stress, activation
of the checkpoint kinases Chk1 (Checkpoint kinase 1), Wee1 and
ATR (Ataxia Telangiectasia and Rad3 related) facilitate S and G2
checkpoint arrest (Sanchez et al., 1997; Liu et al., 2000; Wang
et al., 2001; Heffernan et al., 2002; Sørensen et al., 2003; Beck et al.,
2012). These kinases may promote survival of tumor cells both
in the absence and presence of DNA damaging agents. Inhibitors
of these kinases have been developed and are currently in pre-
clinical and clinical testing for cancer treatment (Do et al., 2013;
Llona-Minguez et al., 2014; McNeely et al., 2014). For instance,
several clinical trials are ongoing with the Wee1 inhibitor MK1775
(AZD1775) for combined treatment with radiation therapy or
chemotherapy. These studies are performed in several cancer
types, including lung cancer. Trials are also ongoing with the
Chk1-inhibitors LY2606368 and SCH 900776 as single agents
or in combination with chemotherapeutic drugs (ClinicalTri-
als.Gov). Of note, non-small cell lung cancer (NSCLC) patients
treated with Chk1 inhibitors reportedly showed partial responses
in Phase 1 trials (Calvo et al., 2014; Sausville et al., 2014). The
first clinical trials with ATR inhibitors were recently initiated,
evaluating the safety and biological effects of AZD6738 and VX-
970 (ClinicalTrials.Gov).
Here, we briefly review the rationales for using checkpoint
kinase inhibitors as anticancer agents, and discuss their potential
for treatment of lung cancer. The focus is on how checkpoint
kinase inhibition in principle can lead to selective killing of lung
cancer cells while sparing the surrounding normal tissue.
GENERAL PRINCIPLES BEHIND THE TUMOR SELECTIVE
EFFECTS OF Chk1/ATR/Wee1 INHIBITORS
G2 CHECKPOINT ABROGATION
Following DNA damage, the G2 checkpoint prevents mitotic
entry of damaged cells and thereby protects against mitotic catas-
trophe and cell death (Syljuåsen et al., 2004). The G2 checkpoint
is activated mainly through inhibition of the mitosis promot-
ing complex Cyclin B-Cdk1 (Cyclin dependent kinase 1). Wee1
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FIGURE 1 | Selective killing of p53 negative tumor cells through G2 checkpoint abrogation by inhibitors of ATR, Chk1, or Wee1. Compared to normal
cells with an intact G1 checkpoint, cancer cells lacking the p53-dependent G1 checkpoint may depend more on the G2 checkpoint to survive after DNA damage.
kinase directly phosphorylates Cdk1 on its Tyrosine 15 residue,
an inhibitory phosphorylation site negatively regulating Cdk1
activity (Parker and Piwnica-Worms, 1992). Tyrosine 15 phos-
phorylation is counteracted by the CDC25 (Cell Division Cycle
25) phosphatases, which in turn are negatively regulated by Chk1
(Sanchez et al., 1997). The activity of Chk1 is stimulated by
ATR-mediated phosphorylation of Chk1 at the Serine 317 and
345 residues (Zhao and Piwnica-Worms, 2001). Thus, inhibition
either of Wee1, Chk1, or ATR leads to decreased inhibitory
phosphorylation of Cdk1 and thereby increased Cdk1 activity and
G2 checkpoint abrogation.
Importantly, it was hypothesized that cancer cells lacking the
G1 checkpoint may depend more on the G2 checkpoint for
cell survival (reviewed in Dixon and Norbury, 2002; Ma et al.,
2011). The G1 checkpoint is activated through the function of
the tumor suppressor p53, and is often absent in cancer cells
due to p53 mutations or other defects in the p53 signaling
pathway (Nagasawa et al., 1995). Abrogation of the G2 checkpoint
by inhibitors of Chk1, Wee1, or ATR may therefore selectively
sensitize p53 defective cancer cells to DNA damaging agents, while
the surrounding normal cells could be spared (Figure 1; Leijen
et al., 2010; Ma et al., 2011; Hirokawa et al., 2014).
S PHASE DAMAGE
While Chk1, Wee1, and ATR are widely known as key regulators
of the G2 checkpoint, these kinases also regulate CDK activity
during S phase, and thereby prevent the induction of DNA
damage during normal S phase progression (Syljuåsen et al.,
2005; Sørensen and Syljuåsen, 2012). Increased CDK activity in
response to checkpoint kinase inhibition promotes unscheduled
replication initiation, leading to nucleotide shortage, replication
stalling and subsequent activation of endonucleases and DNA
breakage (Beck et al., 2012). In addition, shortage of other repli-
cation factors such as RPA (Replication Protein A) contributes to
replication fork collapse after the unscheduled initiation (Toledo
et al., 2013). ATR and Chk1 also play a more direct role in stabi-
lizing stalled replication forks, by mechanisms that are still poorly
understood (Brown and Baltimore, 2003; Friedel et al., 2009), but
may involve suppression of nucleases (Froget et al., 2008; Forment
et al., 2011). Thus, Chk1, ATR, and Wee1 inhibitors do not only
cause G2 checkpoint abrogation, but also induce DNA damage
in S phase, which may contribute to the cytotoxic effects of these
inhibitors (Toledo et al., 2011; Sørensen and Syljuåsen, 2012).
During tumor development, the expression of oncogenes, such
as Cyclin E, Myc and Ras, may abnormally increase replication,
leading to so-called “replication stress” (Bartkova et al., 2005;
Gorgoulis et al., 2005; Halazonetis et al., 2008). Importantly,
cancer cells with elevated replication stress activate ATR/Chk1 and
may depend more on these kinases for cell survival compared to
normal cells (Gilad et al., 2010). In such cells ATR/Chk1 may help
restrain the CDK activity and replication to tolerable levels, and
these cells also likely depend more on Wee1. When combined
with ongoing replication stress caused by oncogenes, checkpoint
kinase inhibitors may therefore cause cytotoxic levels of S phase
damage in tumor cells, while having minimal effects on normal
cells. In addition to G2 checkpoint abrogation in p53 defective
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FIGURE 2 | Selective killing of cancer cells through S phase damage induced by checkpoint kinase inhibitors. Elevated replication stress in cancer cells
due to oncogenes or hypoxia may lead to increased cytotoxic effects of checkpoint kinase inhibitors in S phase.
cells, increased S phase damage thus represents another reason
for tumor-selective effects of Chk1, ATR, and Wee1 inhibitors
(Figure 2; Sørensen and Syljuåsen, 2012; Do et al., 2013; Lecona
and Fernandez-Capetillo, 2014).
INHIBITION OF HOMOLOGOUS RECOMBINATION REPAIR
Another shared function of Chk1, Wee1, and ATR is their role
in positive regulation of homologous recombination (HR) repair,
a major pathway for repair of DNA double strand breaks. In
fact, inhibition of HR repair was suggested as a main mechanism
for the radiosensitizing effects of the Chk1-inhibitor AZD7762,
besides G2 checkpoint abrogation (Morgan et al., 2010). The
Chk1-mediated regulation of HR repair occurs at least partly
through direct phosphorylation of the Rad51 recombinase repair
protein (Sørensen et al., 2005). A recent study showed that
Wee1 inhibition also can inhibit Rad51 function and HR repair
(Krajewska et al., 2013). The increased CDK activity after Wee1
inhibition leads to phosphorylation of BRCA2 at the 3291 residue,
which in turn inhibits Rad51 loading (Davies and Pellegrini, 2007;
Krajewska et al., 2013). The role of ATR in HR repair is less
clear. However, ATR may support HR repair through control of
the S phase checkpoint allowing time for repair, and through
phosphorylation of Chk1 or other factors such as BRCA1 (Brown
et al., 2014).
Notably, HR repair is largely restricted to S and G2 phase
cells (Jeggo et al., 2011), and inhibition of HR repair will thus
not affect non-cycling G0 or G1 phase cells. As tumors typically
contain more cycling cells compared to the surrounding normal
tissues, inhibition of HR repair in S and G2 phase cells therefore
likely contributes to promote tumor selective effects of checkpoint
kinase inhibitors.
CANCER-ASSOCIATED CHANGES IN ATR, Chk1, or Wee1 EXPRESSION
ATR, Chk1, and Wee1 are all essential proteins required for
embryonic development in mice (Brown and Baltimore, 2000;
Liu et al., 2000; Tominaga et al., 2006). Consistent with an
essential role, homozygous inactivating mutations of the genes
encoding these checkpoint kinases have not been observed in
cancer. However, a small subset of human tumors shows het-
erozygous mutations in ATR or Chk1 (Bertoni et al., 1999; Lewis
et al., 2005; Zighelboim et al., 2009), resulting in reduced protein
expression. To our knowledge mutations in Wee1 have not been
reported. However, Wee1 may be downregulated through other
mechanisms such as cancer-associated expression of microRNAs
(Butz et al., 2010; Tili et al., 2011). Interestingly, a recent siRNA
screen identified ATR itself, and regulators of ATR kinase activity,
among the factors protecting cells against the ATR inhibitor
VE821 (Mohni et al., 2014). Cancer cells with reduced expression
of ATR were thus more sensitive to the ATR inhibitor. This is
likely because of more complete ATR inactivation in response
to concentrations of VE821 that normally would be sufficient
to only partially inactivate the cellular pool of ATR. Hence, it
is possible that cancer cells with inherent reduced expression
of ATR, Chk1, or Wee1 may respond to low concentrations
of checkpoint kinase inhibitors, whereby normal cells could be
spared.
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On the other hand, ATR, Chk1, and Wee1 are also overex-
pressed in a subset of human cancers (Iorns et al., 2009; Mir et al.,
2010; Cole et al., 2011; Magnussen et al., 2012; Parikh et al., 2014).
In some cases, the checkpoint kinases may be upregulated as
part of a cellular response to cope with elevated replication stress
(Sørensen and Syljuåsen, 2012; Lecona and Fernandez-Capetillo,
2014). For instance, Myc amplification has been linked with
elevated Chk1 levels and increased sensitivity to Chk1 inhibitors
(Cole et al., 2011; Hoglund et al., 2011). Possibly, such cells will
therefore depend on the high levels of ATR, Chk1, or Wee1 to
survive. Inhibitors of ATR, Chk1, or Wee1 may thus potentially
be more toxic to cancer cells inherently expressing high levels of
these kinases. Taken together, this creates a complex picture where
either abnormal low expression, or high expression, of ATR, Chk1,
or Wee1 in cancer cells may potentially cause increased sensitivity
to inhibitors of these checkpoint kinases.
TUMOR HYPOXIA
Hypoxia is very common in solid tumors and develops due to
rapid growth of cancer cells and insufficient growth of new blood
vessels, resulting in higher oxygen consumption than supply.
Tumors can contain regions of long-term, persistent hypoxia,
as well as regions with fluctuations in oxygen leading to cycles
of transient hypoxia and reoxygenation (Bertout et al., 2008;
Dewhirst, 2009). Hypoxia is a poor prognostic factor and is
associated with resistance to conventional cancer therapy (Bristow
and Hill, 2008; Horsman et al., 2012; Luoto et al., 2013; Walsh
et al., 2014). However, hypoxic tissues also offer the advantage
of being distinct from the surrounding normal tissues, and as
such may be exploited to obtain selective killing of cancer cells.
Importantly, severe hypoxia leads to replication stress and acti-
vation of DNA damage checkpoint signaling (Hammond et al.,
2002, 2003). Therefore, inhibitors of ATR or Chk1 may in fact
represent hypoxic cell cytotoxins (Hammond et al., 2004). Indeed,
several studies have demonstrated increased cytotoxic effects of
both Chk1 and ATR inhibitors in cancer cells exposed to hypoxia
compared to normoxic cells (Hammond et al., 2004; Pires et al.,
2012; Cazares-Korner et al., 2013; Hasvold et al., 2013). How-
ever, the increased effects of Chk1 inhibitors were observed after
reoxygenation following prolonged hypoxic exposure, and not
when the Chk1 inhibitors were present only during hypoxia
(Hasvold et al., 2013). Chk1-inhibitors may thus be more effective
combined with other treatments that cause reoxygenation, such
as for instance fractionated radiotherapy. The impact of hypoxia
on the effects of Wee1 inhibitors is not clear and largely awaits
investigation.
Although more work is needed to elucidate the influence of a
hypoxic tumor microenvironment on the responses to checkpoint
kinase inhibitors, these studies do indicate that hypoxic tumors
may be more sensitive to checkpoint kinase inhibitors compared
to the surrounding normoxic tissue.
CANCER STEM CELLS
Intra-tumor heterogeneity may play an important role during
cancer treatment. Particularly, small sub-populations of tumor-
initiating cells, or cancer stem cells (CSCs), may survive cancer
therapy and promote tumor regrowth. Although the character-
izing markers (Keysar and Jimeno, 2010) and origin of these
cells has been a matter of debate, their existence in human
cancers is now mainly accepted (O’Connor et al., 2014). Due to
their inherent resistance against conventional cancer treatments
and important role in tumor recurrence and metastasis, finding
strategies for eradicating these CSCs is a crucial task.
Interestingly, several studies have demonstrated that DNA
damage-induced signaling is enhanced in CSCs of various origins
(glioblastoma, NSCLC, head and neck, prostate and pancreas),
including increased activation of Chk1, and such cells are par-
ticularly sensitive to Chk1-inhibitors (Bao et al., 2006; Bartucci
et al., 2012; Venkatesha et al., 2012; Wang et al., 2012; Wu et al.,
2012; Fang et al., 2013; Bertrand et al., 2014; Signore et al., 2014).
Furthermore, inhibition of ATR has been shown to cause deple-
tion of chemoresistant and tumorigenic CD133+ colon cancer
cells (Gallmeier et al., 2011), and Wee1 inhibition radio-sensitized
glioblastoma stem cells in vitro (Mir et al., 2010). The expression
of Wee1 was in fact higher in CD133+ compared to CD133− pri-
mary glioblastoma cells (Mir et al., 2010), and Wee1 was among
the most downregulated genes upon differentiation of PTEN
positive glioblastoma stem cells (Forte et al., 2013), indicating
that high levels of Wee1 may be required to maintain a stemlike
state. However, another report found no radio-sensitization by
the Wee1 inhibitor MK1775 in glioblastoma neural stem cells
(Sarcar et al., 2011).
More work is needed to clarify the effects of Chk1 versus ATR
and Wee1 inhibition in CSCs, and to understand the mechanisms
involved. Reports regarding the repair capacity of CSCs have been
conflicting (Bao et al., 2006; McCord et al., 2009; Ropolo et al.,
2009), and the effectiveness of Chk1 inhibition in such cells has
primarily been coupled to regulation of cell cycle progression
and cell death through apoptosis and mitotic catastrophe (Ropolo
et al., 2009).
CHALLENGES OF LUNG CANCER TREATMENT
Excellent reviews summarizing and discussing the various ther-
apies and targets of lung cancer in depth have been published
elsewhere (Willers et al., 2013; Berge and Doebele, 2014; Chen
et al., 2014), and we therefore only briefly summarize some of the
main challenges of current lung cancer treatment below. These
challenges are relevant with respect to evaluating the potential use
of checkpoint kinase inhibitors.
Lung cancer is a common disease, and the number one killer
among cancers (Brustugun et al., 2014). However, there exists
a huge diversity, both in clinical manifestation and patients.
While most patients are or have been daily smokers, some have
never smoked. Many patients are old, but some patients get
this diagnosis at younger age. Traditionally lung cancers were
divided in small cell lung cancer and non-small cell lung cancers.
Current treatment algorithms require both histological subtype
(adenocarcinoma vs. squamous cell carcinomas) and analyses for
specific genetic aberrations. Treatment and follow-up of lung
cancer patients vary depending on these specific characteristics
(Chen et al., 2014).
Approximately 75% of lung cancer patients are diagnosed
with stage four disease, and receive palliative treatment with
chemotherapy and/or radiotherapy. The standard therapy is a
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platinum (cisplatinum or carboplatinum) combined with a sec-
ond drug (gemcitabine, pemetrexed, or vinorelbine for instance).
The effects are unfortunately not long lasting, and new strate-
gies are needed for a more effective treatment (Bonanno et al.,
2014).
A subset of patients is treated with targeted therapy based
on genetic aberrations in the tumor. Approximately 10–15% of
NSCLCs are mutated in the EGFR gene, more common in Asian
populations and among never-smokers. Patients with an EGFR-
mutation in their tumor cells are effectively treated with tyrosine
kinase inhibitors like gefitinib, erlotinib, or afatinib. These drugs
have effects for 8–9 months in median, and second and third line
drugs are in development (Melosky, 2014).
A small percentage of the tumors have a translocation involv-
ing the ALK-gene. This is present in approximately 2–6% of
the adenocarcinomas, and is also effectively treated with tar-
geted therapy (crizotinib, ceritinib; Chia et al., 2014). Unfortu-
nately, resistance develops in all patients. Other genetic alterations
are currently being tested in clinical studies. BRAF mutations,
ROS1 translocations, PIK3CA mutations, MET amplifications
and HER2 aberrations are examples of such alterations, present
in only a small percentage of lung cancers and currently being
targeted in clinical studies (Chen et al., 2014).
Unfortunately, while lung cancer treatment today can relieve
symptoms and prolong life with some months, the disease usually
progresses. More knowledge is therefore needed about mecha-
nisms underlying disease progression in order to develop new
treatment strategies.
THE POTENTIAL OF ATR/Chk1/Wee1 INHIBITORS FOR
TREATMENT OF LUNG CANCER
In light of the general principles behind the tumor selectivity of
ATR, Chk1, and Wee1 inhibitors outlined above (summarized in
Figure 3), there are several specific traits associated with lung
cancer that may potentially increase the efficacy of such inhibitors.
Below we outline these traits and discuss relevant published
experimental work.
p53 MUTATIONS
Firstly, p53 mutations are very common in lung cancer (Takahashi
et al., 1989). This is important as loss of p53 is proposed as
a major reason behind the tumor specific effects of checkpoint
kinase inhibitors (see above). Previous work showed that p53
disruption could sensitize p53 wt lung cancer cells (A549 and
LXSN) to the combined effects of radiation and the Chk1-
inhibitor UCN-01 (Xiao et al., 2002). Similarly, the Wee1 inhibitor
MK1775 radio-sensitized lung cancer cells (A549, H460, H1299)
in a p53-dependent manner (Bridges et al., 2011). Furthermore,
siRNA mediated depletion of p53 sensitized A549 lung cancer
cells to the ATR inhibitor VE821 in combination with cisplatin
FIGURE 3 | Multiple effects of checkpoint kinase inhibitors can potentially contribute to their tumor selectivity. See main text for details.
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(Reaper et al., 2011), and A549 cells depleted of p53 were also
sensitized to another ATR inhibitor, VX-970, in combination with
various DNA damaging drugs (Hall et al., 2014). These results
thus support the hypothesis that inhibitors of ATR, Chk1, or
Wee1 can be used to selectively target p53 deficient lung cancer
cells. However, although p53 status has proven important for the
effects of checkpoint kinase inhibitors in isogenic cell systems,
p53 status alone does not seem sufficient to predict responses
across large heterogenic cancer cell panels (Petersen et al., 2010;
Guertin et al., 2013; Hall et al., 2014). Particularly, the cytotoxic
effects of ATR, Chk1, or Wee1 inhibitors given as single agents
vary between different cell lines regardless of p53 status (Petersen
et al., 2010; Guertin et al., 2013; Hall et al., 2014). It is therefore
unlikely that the p53-status alone can fully predict the efficacy of
ATR, Chk1, and Wee1 inhibitors in lung cancer patients. However,
p53 deficiency is, one among several factors, contributing to
increasing the efficacy of these inhibitors.
INCREASED REPLICATION STRESS CAUSED BY GENETIC ALTERATIONS
OR HYPOXIA
Secondly, replication stress is a common feature of lung can-
cer, which could sensitize to checkpoint kinase inhibition by
enhancing the S phase damage (see above). For instance, the
Myc oncogene is an inducer of replication stress, and some lung
cancers are Myc-driven (Little et al., 1983). Exogenous overex-
pression of Myc caused increased sensitivity to Chk1 inhibitors in
various cell types (Cole et al., 2011; Hoglund et al., 2011; Murga
et al., 2011). In addition, ATR inhibitors caused increased cell
death in Myc overexpressing cells, and partial genetic depletion of
ATR prevented growth of Myc-induced tumors in mice (Murga
et al., 2011; Schoppy et al., 2012). Thus, Myc overexpression
may sensitize to both Chk1 and ATR inhibitors. Furthermore,
Ras is mutated in a subset of lung cancers (Vasan et al., 2014).
Oncogenic Ras can cause replication stress and increase the
efficacy of ATR inhibitors (Gilad et al., 2010; Schoppy et al.,
2012), and the Wee1 inhibitor MK1775 was identified in a screen
for agents targeting Ras driven malignancies (Weisberg et al.,
2014).
In addition, a proportion of NSCLCs reportedly show reduced
expression of the repair protein ERCC1 (Postel-Vinay et al., 2012;
Wei et al., 2012). Low levels of ERCC1 sensitize cells to platinum-
based drugs such as cisplatin, and ERCC1 is currently being tested
as a predictive biomarker for cisplatin-based chemotherapy in
lung cancer (Postel-Vinay et al., 2012; Wei et al., 2012; Bonanno
et al., 2014), although the methods of evaluating the ERCC1
levels have been questioned (Friboulet et al., 2013). Interest-
ingly, a recent siRNA screen for factors protecting against the
ATR inhibitor VE821 identified ERCC1 among the strongest hits
(Mohni et al., 2014). Cells with low levels of ERCC1 ceased S phase
progression and showed increased cell death after ATR and Chk1
inhibition (Mohni et al., 2014). Lung cancer cells with low levels of
ERCC1 may therefore be highly sensitive to ATR, as well as Chk1,
inhibitors.
Thus, manipulation of Myc, Ras or ERCC1 in various cell
systems can cause altered sensitivity to ATR, Chk1, and Wee1
inhibitors. However, it remains to be shown whether Myc, ERCC1
and/or Ras status can predict responses to checkpoint kinase
inhibitors across large panels of heterogenic human lung tumors.
Potentially, these factors could be valuable as predictive biomark-
ers for responses to checkpoint kinase inhibitors in vivo.
Moreover, hypoxia is common in lung tumors (Bollineni et al.,
2012). Hypoxia can induce replication stress (Hammond et al.,
2003) and may sensitize to ATR or Chk1 inhibitors (Olcina
et al., 2010). Nonetheless, few studies have focused on hypoxia
and the effects of checkpoint kinase inhibition in lung cancer. Of
note, a recent report demonstrated decreased viability of hypoxic
A549, H1299, and H1975 lung cancer cell lines after treatment
with a hypoxia-activated Chk1 inhibitor (the CH-01 prodrug;
Cazares-Korner et al., 2013), indicating that hypoxic lung tumors
may be sensitive to Chk1 inhibitors. In contrast, a single study
suggested that hypoxia does not sensitize H1299 lung cancer cells
to the Wee1 inhibitor MK1775 (O’Brien et al., 2013).
LUNG CANCER STEM CELLS
Though less studied than CSCs in glioblastoma, several studies
have suggested that lung tumors contain sub-populations of such
tumor initiating cells (reviewed in Singh and Chellappan, 2014).
High expression levels of CSC markers such as CD133 and CD44
have been identified as poor prognostic factors in NSCLC patients
(Luo et al., 2014; Wu et al., 2014), and studies with lung cancer
cell lines have confirmed the presence of side population (SP)
cells and spheroid-forming cells with typical CSC properties,
including resistance to chemotherapy agents and radiation (Ho
et al., 2007; Salcido et al., 2010; Fang et al., 2013; Lundholm et al.,
2013). Furthermore, recent studies have shown that lung cancer
cell lines surviving radiation express higher levels of several CSC
markers such as CD44 or CD24 (Gomez-Casal et al., 2013).The
cell adhesion molecule CD44 in particular was upregulated in
cells surviving radiation from two different lung cancer cell lines
(Gomez-Casal et al., 2013), suggesting that this marker may be
associated with radiation resistance. CD44 positive cells were also
found to be resistant to cisplatin in a study of NSCLC cell lines
(Leung et al., 2010).
Overcoming such treatment resistance is vital for success-
ful treatment of lung cancer patients, and a few recent studies
indicate that Chk1 inhibition might be a promising way to do
so. In spheroid-forming cells derived from the NSCLC cell line
NCI-H1299, the combination treatment of Chk1 inhibition and
gemcitabine enhanced the antiproliferative effect of gemcitabine,
though it failed to deplete the CSC population completely (Fang
et al., 2013). Even more promising, in a study using cells derived
directly from lung cancer patients, activation of Chk1 in response
to chemotherapeutic drugs was strongly enhanced in cells grown
as spheres (undifferentiated) compared to adherent cells grown in
a monolayer (differentiated; Bartucci et al., 2012). These undiffer-
entiated cells, termed NSCLC-SCs, were also resistant to the cyto-
toxic effects of cisplatin, gemcitabine and paclitaxel, consistent
with a strong repair capacity and checkpoint activation. However,
inhibition of Chk1 abolished this chemotherapy resistance, and
the combination of chemotherapy and Chk1 inhibitors severely
decreased the colony-forming ability of these cells, making Chk1
inhibition a promising strategy for the selective targeting of such
NSCLC-SCs. The effects of ATR and Wee1 inhibitors in this
context are not known.
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ALTERED EXPRESSION LEVELS OF CHECKPOINT KINASES IN LUNG
CANCER
Only limited information is available regarding the expression
levels of ATR, Chk1, and Wee1 in lung cancer. However, ATR
and Chk1 may be amplified in a subset of genomic unstable
lung cancers (Krajewska et al., 2014). In one report, lung cancer
cell lines expressing high levels of Chk1 were hypersensitive to
Chk1 inhibitors, suggesting that their growth depended on the
high amount of Chkl (Grabauskiene et al., 2013). To our knowl-
edge, ATR and Chk1 are not commonly mutated in lung tumors
(http://cancergenome.broadinstitute.org). However, other mech-
anisms of inactivation, like methylation or microRNA-regulation,
might play a role. Loss of Wee1 has been reported in NSCLC
(Yoshida et al., 2004), but it is not known whether these cells show
altered sensitivity to Wee1 inhibitors.
SYNERGY WITH CONVENTIONAL LUNG CANCER TREATMENTS
While checkpoint kinase inhibitors may show antitumor activity
as single agents, they will most likely be used in combination
with other treatments. As described above, the current standard
treatments of lung cancer include several chemotherapeutic drugs
and radiation therapy. Some of these conventional treatments
may synergize with checkpoint kinase inhibitors. Multiple studies
in different cancer types suggest that ATR and Chk1 inhibitors
strongly synergize with gemcitabine and cisplatin (Lecona and
Fernandez-Capetillo, 2014; McNeely et al., 2014). This has also
been shown in lung cancer. Combination of the Chk1 inhibitor
AZD7762 with gemcitabine or cisplatin suppressed growth of
lung carcinoma xenografts in mice (Bartucci et al., 2012). H1299
lung cancer cells grown as spheres were resistant to gemcitabine,
but could be sensitized by Chk1-inhibition (Fang et al., 2013).
In addition, the ATR inhibitor VX-970 sensitized lung cancer cell
lines and human lung tumor primary xenografts to cisplatin (Hall
et al., 2014). Notably, when comparing the effects of combining
the inhibitors with cisplatin or gemcitabine, the ATR inhibitor
VX-970 was most effective in combination with cisplatin, and the
Chk1 inhibitor AZD7762 in combination with gemcitabine (Hall
et al., 2014). Potentiation of the effects of H1299 lung cancer cells
to gemcitabine has also been reported with the Wee1 inhibitor
MK1775 (Hirai et al., 2009). Furthermore, both Chk1 and Wee1
inhibitors were reported to sensitize lung cancer cells to radiation
(Bridges et al., 2011; Yang et al., 2011).
CONCLUDING REMARKS
In conclusion, lung tumors are difficult to treat and inhibitors
of checkpoint kinases ATR, Chk1, and Wee1 will potentially be
useful in future treatment strategies. Several common traits of
lung cancer can contribute to increase the efficacy of checkpoint
kinase inhibitors and promote tumor selective toxicity (summa-
rized in Figure 4). However, as lung tumors are very diverse, the
inhibitors are unlikely to be effective in all patients. The main
challenges are to identify which patients that would benefit from
such treatment and to utilize the inhibitors in the most optimal
ways.
The efficacy of checkpoint kinase inhibitors in lung cancer
is determined by multiple genetic factors, including p53, Myc,
Ras, ERCC1, and the levels of ATR, Chk1, and Wee1 kinases
FIGURE 4 | Specific traits of lung cancer potentially causing tumor
selective effects of checkpoint kinase inhibitors. See main text for details.
themselves. In addition, the efficacy also depends on other factors,
like tumor hypoxia and CSCs. Therefore, it will most likely be
difficult to find a single predictive biomarker for responses to
checkpoint kinase inhibitors in lung cancer. A combination of
several biomarkers may be useful to select patients. In order to
identify optimal biomarkers, future studies should aim at under-
standing mechanisms determining the efficacy of such inhibitors
in lung cancer. For instance, the relative contribution of S phase
damage versus G2 checkpoint abrogation to the antitumor effects
is not well understood. Importantly, the ATR, Chk1, and Wee1
kinases have several distinct functions, which need to be addressed
separately. The inhibitors of each of these kinases may therefore
be applicable in different situations. Recent preclinical studies
have in fact reported synergistic effects when different checkpoint
kinase inhibitors were combined, such as for instance Chk1
and Wee1 inhibitors (Carrassa et al., 2012; Russell et al., 2013;
Chaudhuri et al., 2014; Chia et al., 2014). The exact mechanism
behind this synergy between Chk1 and Wee1 inhibitors is not
known, but may likely involve increased S phase damage (Carrassa
et al., 2012; Chila et al., 2014). Such combinations should be
explored further and be carefully compared to the inhibitors given
as single agents at a range of different concentrations.
However, checkpoint kinase inhibitors will most likely be
employed in combination with conventional current treatments,
such as chemotherapeutic drugs and radiation therapy. Thus, an
important issue is how these inhibitors can be utilized in an opti-
mized way together with standard lung cancer treatments. The
combined effects of checkpoint kinase inhibitors with chemother-
apy and radiation should be further explored in both preclin-
ical as well as clinical lung cancer studies. Particular attention
should be given toward potential effects on lung CSCs. As has
been shown for other treatment combinations, the sequential
treatment timing may also be important (Lund-Andersen et al.,
2014). For instance, the optimal time of administrating Chk1
inhibitors in combination with antimetabolites may be after cells
have arrested in S phase following the antimetabolite treatment
(Grabocka et al., 2014).
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Finally, an important issue is whether partial inhibition of
checkpoint kinases may increase the risk for the development
of genetically unstable normal cells, or potentially lead to more
aggressive tumor cells. Few studies have addressed the issue of
potential increased genomic instability of cells surviving treat-
ment with checkpoint kinase inhibitors. However, genetic studies
from mice suggest that partial, subtle depletion of ATR (by
haploinsufficiency) may cause increased genomic instability and
accelerate Ras driven carcinogenesis (Gilad et al., 2010). On the
other hand, subtle overexpression of Chk1 (by an extra allele of
the Chk1 gene) promoted transformation in another report, likely
due to increased survival of cells undergoing replication stress
(Lopez-Contreras et al., 2012). Low levels of replication stress
may therefore allow proliferation of potentially genetic unstable
cells, while high levels of replication stress results in cell death.
To better evaluate the potential risk associated with checkpoint
kinase inhibition, it might be useful to compare the extent of
genomic instability in cells surviving after treatment with check-
point kinase inhibitors with the instability in cells treated with
conventional DNA damaging agents.
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